Naltrexone Treatment Guidelines

Monitoring and Surveillance

• The American College of Gastroenterology recommends surveillance of liver function tests every 3 to 6 months for patients on long-term naltrexone treatment 1
• Close monitoring (every 2-4 weeks) is necessary when using doses higher than 50 mg/day, as the risk of hepatotoxicity increases with supratherapeutic doses, according to the European Association for the Study of the Liver 2

Special Populations

• Patients with chronic hepatitis C or HIV require essential liver function monitoring, as elevations of enzymes >3x the upper limit of normal occur mainly in patients with chronic hepatitis C, as reported by the Infectious Diseases Society of America 2

Hepatic Safety of Naltrexone and Patient Symptom Reporting

Safety in Severe Liver Disease

• Naltrexone can be used safely in patients with acute hepatitis, hepatic failure, or severe cholestatic liver disease, showing no worsening of liver function in these high‑risk groups. This conclusion is based on a 2009 study published in Journal of Hepatology【3】.

Patient Education and Monitoring Recommendations

• When initiating standard‑dose naltrexone (50 mg/day), patients should be instructed to promptly report any signs of liver injury—including jaundice, dark urine, marked fatigue, or right‑upper‑quadrant abdominal pain—to enable timely evaluation and possible medication adjustment【3】.